Reuters

The FDA (news - web sites) said the study it commissioned from the Institute of Medicine (news - web sites) (IOM) is one of many new measures in response to criticism of the agency's handling of Vioxx, as well as the risks of antidepressants used by children.
"We need to have a look at what we're doing. We think we're doing it right, but there's been criticism because of Vioxx and (antidepressants)," Acting FDA Commissioner Lester Crawford told Reuters in an interview.

More...

Takeover of Indigenous Garifuna Community Hospital

Menstruation Is Fast Becoming Optional

Rare Disease Traced to Sperm Donor

Crohn's Disease Drug Cleared for Children

5-Month-Old Girls in ICU After Separation

Coroner: Peanut Kiss Didn't Cause Death

Feds Probe Kidney Transplant Program

Supermarkets Urge Families to Dinner Table